FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Roy D. Baynes, MD, PhD, will join the company as Senior Vice President, Oncology Therapeutics. In this position, Dr. Baynes will report to Norbert W. Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer and will have responsibility for Gilead’s programs in oncology. Dr. Baynes will also join Gilead’s Executive Committee.